These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30233573)

  • 1. Polyanhydride Nanovaccine Induces Robust Pulmonary B and T Cell Immunity and Confers Protection Against Homologous and Heterologous Influenza A Virus Infections.
    Zacharias ZR; Ross KA; Hornick EE; Goodman JT; Narasimhan B; Waldschmidt TJ; Legge KL
    Front Immunol; 2018; 9():1953. PubMed ID: 30233573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR2 Regulates Vaccine-Induced Mucosal T-Cell Memory to Influenza A Virus.
    Lee W; Kingstad-Bakke B; Kedl RM; Kawaoka Y; Suresh M
    J Virol; 2021 Jul; 95(15):e0053021. PubMed ID: 33952647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model.
    Dhakal S; Loube J; Misplon JA; Lo CY; Creisher PS; Mulka KR; Deshpande S; Mitzner W; Klein SL; Epstein SL
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33627390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination.
    Hemann EA; Kang SM; Legge KL
    J Immunol; 2013 Sep; 191(5):2486-94. PubMed ID: 23885108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection.
    Lopez CE; Zacharias ZR; Ross KA; Narasimhan B; Waldschmidt TJ; Legge KL
    NPJ Vaccines; 2024 May; 9(1):96. PubMed ID: 38822003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyanhydride nanovaccine against swine influenza virus in pigs.
    Dhakal S; Goodman J; Bondra K; Lakshmanappa YS; Hiremath J; Shyu DL; Ouyang K; Kang KI; Krakowka S; Wannemuehler MJ; Won Lee C; Narasimhan B; Renukaradhya GJ
    Vaccine; 2017 Feb; 35(8):1124-1131. PubMed ID: 28117173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.
    Lee YN; Lee YT; Kim MC; Gewirtz AT; Kang SM
    J Immunol; 2016 Mar; 196(6):2637-45. PubMed ID: 26864033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal Introduction of Fc-Fused Interleukin-7 Provides Long-Lasting Prophylaxis against Lethal Influenza Virus Infection.
    Kang MC; Choi DH; Choi YW; Park SJ; Namkoong H; Park KS; Ahn SS; Surh CD; Yoon SW; Kim DJ; Choi JA; Park Y; Sung YC; Lee SW
    J Virol; 2015 Dec; 90(5):2273-84. PubMed ID: 26656713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hughes HR; Brockmeier SL; Loving CL
    Front Immunol; 2018; 9():2255. PubMed ID: 30337924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses.
    Matyushenko V; Kotomina T; Kudryavtsev I; Mezhenskaya D; Prokopenko P; Matushkina A; Sivak K; Muzhikyan A; Rudenko L; Isakova-Sivak I
    Antiviral Res; 2020 Oct; 182():104864. PubMed ID: 32585323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and long-term B-cell responses in the upper airway and lung after influenza A virus infection.
    Boyden AW; Frickman AM; Legge KL; Waldschmidt TJ
    Immunol Res; 2014 Aug; 59(1-3):73-80. PubMed ID: 24838149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.
    Gasper DJ; Neldner B; Plisch EH; Rustom H; Carrow E; Imai H; Kawaoka Y; Suresh M
    PLoS Pathog; 2016 Dec; 12(12):e1006064. PubMed ID: 27997610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal CD8+ T cell responses induced by an MCMV based vaccine vector confer protection against influenza challenge.
    Zheng X; Oduro JD; Boehme JD; Borkner L; Ebensen T; Heise U; Gereke M; Pils MC; Krmpotic A; Guzmán CA; Bruder D; Čičin-Šain L
    PLoS Pathog; 2019 Sep; 15(9):e1008036. PubMed ID: 31525249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs.
    Braucher DR; Henningson JN; Loving CL; Vincent AL; Kim E; Steitz J; Gambotto AA; Kehrli ME
    Clin Vaccine Immunol; 2012 Nov; 19(11):1722-9. PubMed ID: 22933397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Fluids as a Live-Animal Sample Source for Evaluating Cross-Reactivity and Cross-Protection following Intranasal Influenza A Virus Vaccination in Pigs.
    Hughes HR; Vincent AL; Brockmeier SL; Gauger PC; Pena L; Santos J; Braucher DR; Perez DR; Loving CL
    Clin Vaccine Immunol; 2015 Oct; 22(10):1109-20. PubMed ID: 26291090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
    Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
    Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.
    Bernasconi V; Bernocchi B; Ye L; Lê MQ; Omokanye A; Carpentier R; Schön K; Saelens X; Staeheli P; Betbeder D; Lycke N
    Front Immunol; 2018; 9():2060. PubMed ID: 30271406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.